VXRT - Vaxart oral COVID vaccine produces antibodies in nose and respiratory tissues

• A recent study found that Vaxart's ( NASDAQ: VXRT ) oral COVID-19 vaccine produced antibodies in the body's mucosal tissues in the nose and lungs as opposed to the bloodstream with currently authorized COVID vaccines.
• The phase 1 study was conducted by the company and has been published in medRxiv . It has not yet been peer reviewed.
• Study authors say that because the mucosa is the body's first line of defense against an infection, "a vaccine that induces a mucosal [Immunoglobulin A (IgA)] response could be an important strategy in curbing the global pandemic."
• The study showed that some participants still had antibody responses up to one year after receiving the vaccine pill.
• In addition, results indicated that the pill, VXA-CoV2-1, was cross-reactive, providing an antibody response against the Delta and Omicron variants as well.
• Vaxart ( VXRT ) recently adjourned a shareholder meeting vote to Aug. 4 to garner more votes on increasing the number of common shares .

For further details see: